The right to be forgotten reduces financial toxicity in cancer survivors
Reduced access to insurance, bank loans and mortgages makes financial constraints continue long after cancer has been treated
More than one in six cancer patients experience long-term effects of COVID-19
OnCOVID study reveals that respiratory symptoms, fatigue and cognitive/psychological dysfunction persist after acute Sars-CoV-2 infection, with an impact on survival and oncological outcomes after recovery
From empiric testing to rational design: two decades of progress in phase I trials
Ensuring equitable access to innovative treatments is now the major challenge in oncology, says Prof. Alex Adjei
Translating research ideas into patient benefits
Investigations are time-consuming and expensive, so greater public funding is needed, according to Prof. George Coukos
Precision oncology is the goal today, not a simple slogan
Prof. Lisa Licitra: “Truly pursuing precision medicine means pushing the boundaries of patient selection using molecular biology and artificial intelligence on all big data, not just molecular information”
Present and Future of Cancer Immunotherapy
The current evidence suggests that a large proportion of patients not responding to PD-1/PD-L1-targeted agents do not have PD-L1-expressing tumours
Recognising Excellence in Oncology: ESMO Awards 2020
Lectures from this year’s ESMO awards recipients kick off the week leading up to the Education weekend of the ESMO Virtual Congress 2020
The Future of Genetics-led Cancer Therapeutics
A key advance in the fight against cancer is the availability of multiple treatment modalities developed to target different aspects of tumourigenesis and maintenance of cancer
The Promise of Combining Adoptive Cell Therapy With Checkpoint Inhibitors
At ESMO Virtual Congress 2020, the first report of clinical responses in multiple solid tumour subtypes increases knowledge on safety of tumour-infiltrating lymphocyte-based adoptive cell therapy combined with immunotherapy.
Long-term Follow-up of the MERIT Trial Reveals Durable Nivolumab Efficacy
Immunotherapy as second- and third-line treatment is effective in pre-treated malignant pleural mesothelioma